3-(cyclohexyloxy)propionic acid | 27912-81-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(cyclohexyloxy)propionic acid
• 英文别名: 3-cyclohexyloxy-propionic acid；3-Cyclohexyloxy-propionsaeure；3-(Cyclohexyloxy)propanoic acid；3-cyclohexyloxypropanoic acid
• CAS: 27912-81-8
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: ZJSQESLWZHBXSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(cyclohexyloxy)propionic acid 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-(cyclohexyloxy)-1-propanol methanesulfonate (ester)
  参考文献：
  名称：

  Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds

  摘要：

  A novel series of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA(2) receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (14) with K-d = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, "shunt" effect to elevate PGI(2) level, and absence of agonist activity.

  DOI：

  10.1021/jm980173n
• 作为产物：
  描述：

  3-苯氧基丙酸 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 24.0 ℃ 、344.73 kPa 条件下， 反应 23.0h， 以89%的产率得到3-(cyclohexyloxy)propionic acid
  参考文献：
  名称：

  Lunney; Hagen; Domagala, Journal of Medicinal Chemistry, 1994, vol. 37, # 17, p. 2664 - 2677

  摘要：

  DOI：

文献信息

• IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
  申请人：KNOPP BIOSCIENCES LLC

  公开号：US20160031875A1

  公开（公告）日：2016-02-04

  Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

  由公式1表示的化合物可能对Kv7.2/7.3异源多聚体具有强效和/或部分选择性。它们可能在治疗与癫痫、疼痛、神经递质释放等相关的疾病方面有用。
• Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
  申请人：Knopp Biosciences LLC

  公开号：US10106536B2

  公开（公告）日：2018-10-23

  Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

  式 1 所代表的化合物对 Kv7.2/7.3 异源二聚体具有强效和/或部分选择性。它们可用于治疗与癫痫发作、疼痛、神经递质释放等有关的疾病。
• Takahashi et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1958, vol. 78, p. 1,3
  作者：Takahashi et al.

  DOI：——

  日期：——
• 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANSÄURE DERIVATE UND VERWANDTE VERBINDUNGEN ALS PPAR MODULATOREN ZUR BEHANDLUNG VON TYP 2 DIABETES UND ATHEROSKLEROSE
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1599455A1

  公开（公告）日：2005-11-30
• IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
  申请人：Knopp Biosciences LLC

  公开号：US20190002464A1

  公开（公告）日：2019-01-03

  Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.